Objective: to estimate the quality of antiaggregants therapy in patients with coronary heart disease in outpatient settings. Materials and methods. The data of the retrospective outpatient RECVAD registry (3690 patients who lived in Ryazan and its Region and had evidence in their outpatient medical records for one of the diagnoses, such as coronary heart disease, hypertension, chronic heart failure, atrial fibrillation, or their concurrence, were used. Fortynine patients after acute myocardial infarction (AMI) and/or percutaneous coro nary interventions (PCI) with stenting ≤ 1 year before their inclusion in the registry, who were to undergo dual antiaggregant therapy (DAT) according to current clinical guidelines (CG), were identified among 427 patients after AMI and/or PCI with coronary angioplasty. Contra indications to DAT were simultaneously revealed and a relationship of the use of therapy to their presence was compared. Results. Among the 49 patients who had indications for DAT that was used in 15 (30.6 %) cases and that was not in 3 (6.1 %) patients in the presence of contraindications, 25 (51.0 %) did not receive DAT in the absence of contraindications and 6 (12.3 %) patients received the therapy in the presence of contraindications. Conclusion. DAT prescribed by outpatient physicians does not always meet the current CG. There are cases of not using DAT in the presence of obvious indications for DAT and, on the contrary, those of its use in the presence of contraindications.